Cobalamin C (cblC) deficiency, the most common inborn error of intracellular cobalamin metabolism, is caused by mutations in MMACHC, a gene responsible for the processing and intracellular trafficking of vitamin B12. This recessive disorder is characterized by a failure to metabolize cobalamin into adenosyl- and methylcobalamin, which results in the biochemical perturbations of methylmalonic acidemia, hyperhomocysteinemia and hypomethioninemia caused by the impaired activity of the downstream enzymes, methylmalonyl-CoA mutase and methionine synthase. Cobalamin C deficiency can be accompanied by a wide spectrum of clinical manifestations, including progressive blindness, and, in mice, manifests with very early embryonic lethality. Because zebrafish harbor a full complement of cobalamin metabolic enzymes, we used genome editing to study the loss of mmachc function and to develop the first viable animal model of cblC deficiency. mmachc mutants survived the embryonic period but perished in early juvenile life. The mutants displayed the metabolic and clinical features of cblC deficiency including methylmalonic acidemia, severe growth retardation and lethality. Morphologic and metabolic parameters improved when the mutants were raised in water supplemented with small molecules used to treat patients, including hydroxocobalamin, methylcobalamin, methionine and betaine. Furthermore, mmachc mutants bred to express rod and/or cone fluorescent reporters, manifested a retinopathy and thin optic nerves (ON). Expression analysis using whole eye mRNA revealed the dysregulation of genes involved in phototransduction and cholesterol metabolism. Zebrafish with mmachc deficiency recapitulate the several of the phenotypic and biochemical features of the human disorder, including ocular pathology, and show a response to established treatments.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399538PMC
http://dx.doi.org/10.1093/hmg/ddaa044DOI Listing

Publication Analysis

Top Keywords

cblc deficiency
12
vitamin b12
8
methylmalonic acidemia
8
mmachc mutants
8
mmachc
6
cobalamin
5
deficiency
5
b12 processing
4
processing enzyme
4
enzyme mmachc
4

Similar Publications

Late-onset renal TMA and tubular injury in cobalamin C disease: a report of three cases and literature review.

BMC Nephrol

October 2024

Renal Division, Department of Medicine, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, 100034, China.

Article Synopsis
  • Mutation of the MMACHC gene causes cobalamin C disease (cblC), leading to symptoms like metabolic disorders and kidney issues, including thrombotic microangiopathy (TMA).
  • Three teenage patients were diagnosed with renal complications from cblC, showing symptoms such as hematuria and hypertension, with tests confirming elevated homocysteine and kidney damage.
  • Early diagnosis and treatment with hydroxocobalamin, betaine, and L-carnitine significantly improved their condition, underscoring the need for awareness of cblC in patients with unexplained kidney injury.
View Article and Find Full Text PDF
Article Synopsis
  • Cobalamin C defect, caused by pathogenic variants in the MMACHC gene, disrupts vitamin B12 metabolism, leading to high homocysteine and low methionine levels in patients.
  • A study at AKUH analyzed 33 Pakistani patients, revealing a median age of symptom onset at 300 days and common issues like cognitive impairment and seizures.
  • Gene analysis showed a predominant pathogenic variant, highlighting late diagnoses and the need for better awareness and diagnostic resources in Pakistan.
View Article and Find Full Text PDF

Methylmalonic acidemia (MMA), propionic acidemia (PA), and cobalamin C deficiency (cblC) share a defect in propionic acid metabolism. In addition, cblC is also involved in the process of homocysteine remethylation. These three diseases produce various phenotypes and complex downstream metabolic effects.

View Article and Find Full Text PDF
Article Synopsis
  • Cobalamin C (Cbl-C) defect leads to serious health issues like methylmalonic acidemia and cognitive impairment, but treatment with hydroxocobalamin (OH-Cbl) doses remains uncertain.
  • * A study compared high-dose OH-Cbl treatment in newborn screening (NBS)-diagnosed patients to low-dose treatment in other groups, showing that the high-dose group had significantly better metabolic and neurodevelopmental outcomes.
  • * Results indicated that while high-dose treatment improved overall health markers and cognitive performance, it did not affect the incidence of maculopathy, signaling a need for clearer dosing guidelines in Cbl-C treatment.*
View Article and Find Full Text PDF
Article Synopsis
  • Nephrotic syndrome can arise from various causes, including metabolic disorders like cobalamin C (cblC) defect, which is linked to mutations in the MMACHC gene affecting vitamin B12 processing and is usually characterized by hematological and neurological symptoms.
  • A 7-month-old male patient's case is presented, showcasing symptoms such as fatigue, edema, and laboratory findings that indicated anemia and proteinuria, eventually leading to a diagnosis of nephrotic syndrome caused by the cblC defect confirmed by genetic testing.
  • The case emphasizes the importance of identifying metabolic conditions in atypical nephrotic syndrome presentations and suggests that early detection and management can prevent serious complications, such as irreversible renal damage.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!